,ug/ml). When the effects of MRDs A and C and TCM on the growth of mammalian cells were compared, MRDs did not show any toxicity, even at 1,000 ,ug/ml, whereas TCM inhibited the growth of BALB/3T3 cells at 10 ,ug/ml. On the basis of these results, it was concluded that MRDs are the first specific and potent inhibitors of the translocase reaction in bacterial peptidoglycan synthesis, showing a high level of toxicity against bacteria and a low level of toxicity against mammalian cells. A specific inhibitor of translocase could be a potent antibiotic with highly selective toxicity.
BaciUlus subtilis of lipid-linked N-acetylglucosamine for teichoic acid synthesis (IC50s, > 100 p,g/ml). In contrast, tunicamycin (TCM) inhibited strongly the formation of Dol-p-p-GlcNAc (IC50, 0.03 ,ugIml) but inhibited weakly the formation of bacterial lipid intermediate I (IC50, 44 ,ug/ml). When the effects of MRDs A and C and TCM on the growth of mammalian cells were compared, MRDs did not show any toxicity, even at 1,000 ,ug/ml, whereas TCM inhibited the growth of BALB/3T3 cells at 10 ,ug/ml. On the basis of these results, it was concluded that MRDs are the first specific and potent inhibitors of the translocase reaction in bacterial peptidoglycan synthesis, showing a high level of toxicity against bacteria and a low level of toxicity against mammalian cells. A specific inhibitor of translocase could be a potent antibiotic with highly selective toxicity.
The novel peptidylnucleoside antibiotics mureidomycins (MRDs) A and C ( Fig. 1) , are structurally new types of bacterial peptidoglycan synthesis inhibitors (3) (4) (5) (6) (7) . They are produced by Streptomyces flavidovirens and have selective and potent in vitro and in vivo activities against Pseudomonas aeruginosa. The MICs of MRD C are as follows:
Staphylococcus aureus FDA 209P JC-1, >200 ,ug/ml; Escherichia coli NIHJ JC-2, >200 ,ug/ml; P. aeruginosa 1046, 1.56 ,ug/ml; and P. aeruginosa NCTC 10490, 0.4 ,ug/ml (6) . MRD A has almost the same MICs as MRD C, although the MICs of MRD A are a little higher. MRDs A and C have a low level of toxicity and can protect mice from P. aeruginosa infections (6) . The reason for the low level of toxicity of MRDs in mice is very interesting. MRDs inhibit peptidoglycan synthesis through the inhibition of translocase, which catalyzes the formation of undecaprenyl pyrophosphoryl N-acetylmuramyl-pentapeptide (lipid intermediate I) from UDP-N-acetylmuramyl-pentapeptide (UDP-MurNAc-pentapeptide) and undecaprenyl phosphate (4). Three antibiotics have been reported to inhibit this translocase. They are tunicamycin (TCM; Fig. 1 ) (14) , amphomycin (APM) (9) , and liposidomycin (LSM) (10) . Among them, TCM and APM are toxic against mammalian cells. They inhibit not only bacterial translocase but also mammalian enzymes that catalyze the formation of lipid-linked saccharides (8, 13) , through which membrane and secreted proteins are glycosylated. There is no report on LSM. Therefore, the inhibition of translocase by MRDs is not sufficient to explain their selective toxicity. In this report, we show that MRDs have a low level of toxicity against mammalian cells because they inhibit neither mammalian nor bacterial lipid-linked saccharide formation but inhibit bacterial translocase. mg of protein from ether-treated bacteria, and various concentrations of MRD A, MRD C, or TCM was incubated without UDP-N-acetylglucosamine (UDP-GlcNAc), and radioactivity incorporated into the n-butanol-extractable fraction was counted with Picofluor (Packard).
Assay of Dol-p-p-GIcNAc. For the assay of dolichyl pyrophosphoryl N-acetylglucosamine (Dol-p-p-GlcNAc) formation, microsomes were prepared from 8-week-old Donryu rat livers (13) and suspended in 10 mM Tris-maleate buffer (pH 7.1) containing 0.1 M KCl. A reaction mixture containing microsomes, Tris-maleate buffer, 0.1 M KCl, 5 mM MnCl2, 5 mM MgCl2, 5 mM 2-mercaptoethanol, 0.1% Triton X-100, 0.1 ,uCi of [3H]UDP-GlcNAc per ml, and various concentrations of MRD A, MRD C, or TCM was incubated at 28°C for 12 min. Labeled lipids were then extracted and processed as described previously (13) .
Assay of lipid-linked GIcNAc formation in Bacillus subtilis. Cells of B. subtilis NA64 grown in Trypto-soy broth at 37°C were collected at the late log phase of growth by centrifugation at 10,000 x g for 15 min at 4°C and washed twice with 50 mM Tris-maleate buffer (pH 7.1) containing 2 mM dithiothreitol. They were then suspended in the same buffer containing 0.5 M sucrose, 5 mM MgCl2, and 300 ,ug of lysozyme per ml and allowed to stand at 37°C for 50 min to make protoplasts. After protoplasts were collected by centrifugation at 8,000 x g for 10 min, they were ,ug/ml, respectively (Fig. 2) . MRD C was as potent as MRD A. Kimura et al. (10) reported that LSM was more potent than TCM against the E. coli enzyme; the IC50s were 0.038 and 12 ,ug/ml, respectively. The IC50 of APM against Bacillus megaterium translocase is about 20 ,ug/ml (15) . Therefore, the MRDs and LSM seem to be much more potent inhibitors of translocase than TCM and APM.
TCM and APM have been shown to inhibit mammalian enzymes that catalyze the formation of lipid-linked saccharides from nucleotide sugars and dolichyl phosphate. Although the substrates are somewhat different from those of bacterial translocase, mammalian lipid-linked saccharide formation seems to be catalyzed by a mechanism similar to that of bacterial translocase. TCM (13) and APM (1) contain a long fatty acid side chain that is supposed to be necessary for their inhibitory activity not only against bacterial translocase but also against mammalian enzymes. LSM (10) also contains fatty acids, but there has been no report on its activity against mammalian enzymes. Since MRDs are unique in that they consist of only nucleoside and peptide moieties (Fig. 1 ), we were interested in testing whether MRDs would inhibit mammalian lipid-linked saccharide formation.
Labeled nucleotide sugars were incubated with microsomes prepared from rat liver, and incorporation into the lipid fraction was measured as described previously (13) . As shown in Fig. 3 against the mammalian enzyme was ca. >2,500 times higher than that against bacterial translocase, a result in clear contrast to the inhibitory activities of TCM and APM. TCM inhibited Dol-p-p-GlcNAc formation preferentially, as shown in Fig. 3 . APM has been reported to inhibit both dolichyl phosphoryl mannose formation and Dol-p-pGlcNAc formation at nearly the same concentration as that needed to inhibit bacterial translocase (8, 9) .
Another step of glycoconjugate synthesis in bacteria in which lipid-linked saccharides participate is the synthesis of teichoic acid. As shown in Table 1 , MRD A did not inhibit lipid-linked GlcNAc formation in the B. subtilis membrane, even at a concentration of 100 ,ug/ml, although TCM inhibited this process nearly completely at the same concentration. The IC50 of TCM was about 0.8 ,ug/ml. Thus, MRDs are the first specific inhibitors of the UDPMurNAc-pentapeptide translocase, which catalyzes the first step of the lipid cycle in bacterial peptidoglycan synthesis. MRDs did not significantly affect mammalian or bacterial lipid-linked saccharide formation, except in peptidoglycan synthesis.
As each MRD consists of four or five amino acids and a pseudouridine nucleoside, the MRDs would be recognized as analogs of UDP-MurNAc-pentapeptide, a distinctive substrate of translocase. In contrast, TCM and APM would mimic in part lipid and/or nucleotide moieties of substrates or intermediates of both mammalian and bacterial reactions. This mimicry may explain why these two antibiotics inhibit nonselectively both bacterial and mammalian enzymes. Tris-maleate buffer containing 300 ,ug of lysozyme per ml to make protoplasts. After protoplasts were collected, they were burst by suspension in Trismaleate buffer containing 50 pLg of DNase I per ml at 0'C for 10 min. The membrane fraction was homogenized, and lipid-linked GIcNAc formation was measured as described in Materials and Methods.
It is well known that TCM selectively blocks the glycosylation of membrane and secreted proteins in mammalian cells (2) , thereby preventing their normal functioning. As a result, TCM is toxic for mammalian cells. In fact, TCM inhibited the growth of BALB/3T3 fibroblasts (Fig. 4) As reported in this paper, although MRDs may mimic only the UDP-MurNAc-pentapeptide moiety, one of the substrates of translocase, they have strong and highly selective inhibitory activity against translocase. A specific inhibitor of bacterial translocase that does not mimic a lipid moiety could be a potent antibiotic with highly selective toxicity against bacteria. Translocase may become a new target for therapeutic antibiotics, as many beta-lactam antibiotics have been synthesized as inhibitors of transpeptidase.
